Bioforce Nanosciences Holdings Stock Net Income
| BFNH Stock | USD 0.57 0.02 3.39% |
As of the 10th of February, BioForce Nanosciences shows the Mean Deviation of 1.55, standard deviation of 3.86, and Risk Adjusted Performance of (0.04). BioForce Nanosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
BioForce Nanosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing BioForce Nanosciences' valuation are provided below:BioForce Nanosciences Holdings does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. BioForce |
BioForce Nanosciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to BioForce Nanosciences' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of BioForce Nanosciences.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in BioForce Nanosciences on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding BioForce Nanosciences Holdings or generate 0.0% return on investment in BioForce Nanosciences over 90 days. BioForce Nanosciences is related to or competes with China Foods, Inter-Rock Minerals, Hanover Foods, Elamex SA, and Integrated Biopharma. BioForce Nanosciences Holdings, Inc. focuses on providing natural vitamins, minerals, other nutritional supplements, pow... More
BioForce Nanosciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure BioForce Nanosciences' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess BioForce Nanosciences Holdings upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 26.54 | |||
| Value At Risk | (6.67) | |||
| Potential Upside | 2.04 |
BioForce Nanosciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioForce Nanosciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as BioForce Nanosciences' standard deviation. In reality, there are many statistical measures that can use BioForce Nanosciences historical prices to predict the future BioForce Nanosciences' volatility.| Risk Adjusted Performance | (0.04) | |||
| Jensen Alpha | (0.19) | |||
| Total Risk Alpha | (0.65) | |||
| Treynor Ratio | 0.5377 |
BioForce Nanosciences February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | 0.5477 | |||
| Mean Deviation | 1.55 | |||
| Coefficient Of Variation | (1,804) | |||
| Standard Deviation | 3.86 | |||
| Variance | 14.93 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.19) | |||
| Total Risk Alpha | (0.65) | |||
| Treynor Ratio | 0.5377 | |||
| Maximum Drawdown | 26.54 | |||
| Value At Risk | (6.67) | |||
| Potential Upside | 2.04 | |||
| Skewness | (0.36) | |||
| Kurtosis | 8.24 |
BioForce Nanosciences Backtested Returns
BioForce Nanosciences secures Sharpe Ratio (or Efficiency) of close to zero, which signifies that the company had a close to zero % return per unit of risk over the last 3 months. BioForce Nanosciences Holdings exposes twenty different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm BioForce Nanosciences' Standard Deviation of 3.86, mean deviation of 1.55, and Risk Adjusted Performance of (0.04) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of -0.42, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning BioForce Nanosciences are expected to decrease at a much lower rate. During the bear market, BioForce Nanosciences is likely to outperform the market. At this point, BioForce Nanosciences has a negative expected return of -0.0182%. Please make sure to confirm BioForce Nanosciences' value at risk, as well as the relationship between the rate of daily change and period momentum indicator , to decide if BioForce Nanosciences performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.11 |
Insignificant reverse predictability
BioForce Nanosciences Holdings has insignificant reverse predictability. Overlapping area represents the amount of predictability between BioForce Nanosciences time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of BioForce Nanosciences price movement. The serial correlation of -0.11 indicates that less than 11.0% of current BioForce Nanosciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.11 | |
| Spearman Rank Test | -0.23 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, BioForce Nanosciences Holdings reported net income of (501,955). This is 100.05% lower than that of the Consumer Defensive sector and 99.49% lower than that of the Packaged Foods industry. The net income for all United States stocks is 100.09% higher than that of the company.
BioForce Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioForce Nanosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of BioForce Nanosciences could also be used in its relative valuation, which is a method of valuing BioForce Nanosciences by comparing valuation metrics of similar companies.BioForce Nanosciences is currently under evaluation in net income category among its peers.
BioForce Fundamentals
| Return On Asset | -21.84 | |||
| Current Valuation | 50.2 M | |||
| Shares Outstanding | 29.27 M | |||
| Shares Owned By Insiders | 82.29 % | |||
| Price To Earning | (1.52) X | |||
| Price To Book | 866.24 X | |||
| Price To Sales | 3,841 X | |||
| Gross Profit | 4.36 K | |||
| EBITDA | (501.95 K) | |||
| Net Income | (501.95 K) | |||
| Cash And Equivalents | 9.23 K | |||
| Total Debt | 156.87 K | |||
| Debt To Equity | 4.61 % | |||
| Current Ratio | 0.01 X | |||
| Book Value Per Share | (0.04) X | |||
| Cash Flow From Operations | (77.77 K) | |||
| Earnings Per Share | (0.02) X | |||
| Target Price | 0.25 | |||
| Beta | -1.93 | |||
| Market Capitalization | 72.74 M | |||
| Total Asset | 11.14 K | |||
| Retained Earnings | (21 K) | |||
| Working Capital | 14 K | |||
| Current Asset | 15 K | |||
| Current Liabilities | 1 K | |||
| Net Asset | 11.14 K |
About BioForce Nanosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioForce Nanosciences Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioForce Nanosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioForce Nanosciences Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in BioForce Pink Sheet
BioForce Nanosciences financial ratios help investors to determine whether BioForce Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioForce with respect to the benefits of owning BioForce Nanosciences security.